[ad_1]
Now the drug is included Xeljanz, tofacitinib, for the treatment of ulcerative colitis and psoriatic arthritis in high cost protection. The preparation has already been included in high cost protection for the treatment of rheumatoid arthritis, RA.
Psoriatic arthritis is a chronic inflammatory joint disease that has some connection with psoriasis. Xeljanz is indicated for the treatment of active psoriatic arthritis in adult patients who have had a poor response or who do not tolerate one or more disease-modifying antirheumatic drugs modifying the course of the disease.
Xeljanz contains the active substance tofacitinib, a Januskinase Inhibitor (JAK). Inhibition of JAK causes a decrease in inflammation.
TLV has below In 2017, tripartite consultations were held with companies and county councils in the area of TNF inhibitors and JAK inhibitors. As part of these deliberations, county councils and companies signed a parallel agreement for Xeljanz. This page agreement covers all sales of the product.
Considering The contents of the parallel agreement with Xeljanz believes that the cost of treatment with Xeljanz against ulcerative colitis is lower than the cost of comparison options, including the drug of attention. Humira whose patent was published in the autumn. And for psoriatic arthritis, TLV believes that Xeljanz does not exceed the era of the pretreatment considered reasonable for the disease.
[ad_2]
Source link
